-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 15th, Kang Enbei issued an announcement saying that it agreed to its wholly-owned subsidiary Hangzhou Kang Enbei to invest RMB 100 million in the transfer of the total flavonoids extract of the hollyhock flower and the total flavonoids of the hollyhock flower oral patch owned by Shandong Academy of Pharmaceutical Sciences.
Technology and research materials, clinical trial approval documents and all related intellectual property rights; agree to authorize the company's management and management to cooperate with Hangzhou Kang Enbei to handle related matters including but not limited to the signing of the "Technology Transfer Contract"
.
The company’s wholly-owned subsidiary Hangzhou Kangenbei invested RMB 100 million to acquire the rights and interests of the total flavonoid extract of hollyhock flower and oral patch of hollyhock flower total flavonoids owned by Shandong Academy of Pharmaceutical Sciences.
The transaction pricing is based on the following:
(1) Refer to the cost of the company and other scientific research units independently developing new Chinese medicine products
.
The main cost is the average expenditure cost and time cost in the process from project establishment, clinical trials to obtaining the drug registration certificate, combined with the difficulty of the specific product process and the cost of equipment for R&D and test equipment
With reference to the R&D investment of the company's independent research and development of new Chinese medicines: Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
(stock code: 600557, hereinafter referred to as "Kangyuan Pharmaceutical") disclosed Lin 2020-008 on April 20, 2020 Announcement of Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
on Obtaining Drug Registration Approval", Kangyuan Pharmaceutical received the "Drug Registration Approval" issued by the State Food and Drug Administration in April 2020, and its self-developed muscle and bone pain relief gel obtained Chinese medicine 6.
1 new drug approval documents
.
Kangyuan Pharmaceutical has invested RMB 43,345,900 in the research and development of the bone pain relief gel project
(2) Refer to the pricing level and public transfer price of relevant technologies and rights in each research stage of new Chinese medicine varieties in the current technology transfer market
.
On the basis of the counterparty’s quotation, the company negotiated with the counterparty and finally reached an agreement after internal investigation, research and discussion, and reference to the transfer price of similar new Chinese medicines in the market, to acquire the rights and interests of the total flavonoid extract of hollyhock flower and oral patch for 100 million yuan
With reference to the pricing of new Chinese medicines through technology transfer in the market: Beijing Kangchen Pharmaceutical Co.
, Ltd.
(stock code: 603590, hereinafter referred to as "Kangchen Pharmaceutical") disclosed Lin No.
2018-020 "Beijing" on November 8, 2018 Announcement of Kangchen Pharmaceutical Co.
, Ltd.
on the Signing of Technology Transfer Contracts", Kangchen Pharmaceuticals has obtained its five-class new Chinese medicine Jin Gu Cao total iridoid glycoside tablets (hereinafter referred to as "Jincao Tablets") under development.
Two invention patents were authorized, one invention patent application under actual examination, "Drug Clinical Research Approval Document", and all technical data were transferred to Beijing Jiulong Company for RMB 98 million
.
This variety was currently in the clinical research stage, and the Phase I clinical study has been completed.
After the two parties of the transaction, Hangzhou Conba Company (Party A) and Shandong Academy of Pharmaceutical Sciences (Party B) have negotiated and communicated many times, and reached an agreement on the main terms of the "Technology Transfer Contract" to be signed, and it is planned to be on September 18, 2021.
Complete signing
.
According to the contract, the total cost of this technology transfer is 100 million yuan (including tax), and the payment will be made in the following six installments.
Phase 1: Within ten working days after the signing of this contract, A remittance of RMB 20 million to the account designated by Party B (20% of the total contract amount);
Phase II: After the signing of this contract takes effect, Party B will assist Party A in submitting a supplementary application for the change of the applicant to the State Food and Drug Administration and the Center for Drug Evaluation, and the State Food and Drug Administration and Center for Drug Evaluation shall formally approve the change (or enter the Hangzhou Kangenbei is the applicant’s next review) within ten working days, A shall remit RMB 20 million (20% of the total contract amount) to the account designated by Party B;
Phase 3: After the signing of this contract takes effect, Party B assists Party A to complete at least three consecutive batches of production process verification according to the registered process, and the product meets the relevant requirements of quality standards and quality comparison studies, obtains product qualification inspection reports and completes related quality comparisons Within ten working days after the research, A remits RMB 20 million to the account designated by Party B (20% of the total contract amount);
Fourth period: Within ten working days after Party A obtains the drug registration certificate, Party A shall remit RMB 25 million (25% of the total contract amount) to the account designated by Party B;
Phase 5: Within ten working days after completing the 24-month long-term stability research data of the three batches of products and meeting the quality standards, A to Party B’s designated account shall remit RMB 1,000,000 (6% of the total contract amount).
Phase 6: Within ten working days after the completion of the follow-up research agreement agreed by both parties (see attachment) for the project, A remits RMB nine million to the account designated by Party B (9% of the total contract amount)
